Entering text into the input field will update the search result below

CEL-SCI: Enduring Challenges

Out of Ignorance profile picture
Out of Ignorance


  • CEL-SCI's long-time CEO Geert Kersten has faced down CEL-SCI challenges for decades; he is currently facing his toughest challenge.
  • CEL-SCI shareholders have endured multiple challenges, not the least of which has been its three reverse splits.
  • While CEL-SCI appears to have its current financial needs under control, it has no cushion to fall back on if Multikine's approval process gets drawn out.
  • CEL-SCI's most important and difficult challenge is securing FDA approval for its Multikine therapy.
Lonely tree in concrete

nurulanga/iStock via Getty Images

I last addressed CEL-SCI (NYSE:CVM) in 02/2022's "CEL-SCI: No Rush Here". At the time I concluded:

Given the lack of any discernible progress or guidance on when to expect a filing for Multikine with the FDA, I now rate it charitably

This article was written by

Out of Ignorance profile picture
Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share relevant anecdotes and experiences.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ANY COMPANY MENTIONED over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (15)

This is a scam co it seems nothing to see.

Always Jam tomorrow.

I can't imagine they have any patent protection left at this point any how
manpower profile picture
Multikine results have been posted on ClinicalTrials.gov on Aug 19th 2022. A required step on the path to attain FDA approval. www.clinicaltrials.gov/...
Change your name to "out of intelligence" I got into CVM before the 2nd reverse split and kept buying as it went down and through a 3rd reverse split, I have a lot of shares (more than soosheigh ever had I'll wager, ) . since 2018 I have lent over 60000 shares a day to shorts at obscene rates of interest such that my total cost per share (paid-$interest)/#shares is probably under 25 cents before taxes. I also have made a few $ selling lo cost medium term puts. CVM is a binary type stock that can revolutionize cancer tumor treatment if BP will let it develop. I put my bucks where my gut tells me, and earnings and charts at this time are irrelavent. If you want to make or lose dollars day trading. good luck.
Out of Ignorance profile picture
Obviously mathematics is your forte, english not so much.
"I regard CEL-SCI as too risky for anyone other than a day trader." Definitely not an endorsement of day trading.
When you hear a CEO talking about shorts like some lunatic in social media. Run away fast.
Out of Ignorance profile picture
That is an excellent rule of thumb.
BioSlammer profile picture
North shore research aka Sushifishman had been actively bashing cvm lately trying to get cheaper shares. He coordinates with this particular quest so everything in this article goes to the short argument.
Notice the comment "ten year string of clinical trials". Really? There was one trial that lasted meet ten years because apparently overall survival was extended by 4+ years in the predefined arm of the trial that received radiation and surgery versus chemo radiation and surgery. The chemo arm did not fare as well but there's an awful lot of people walking around happy right now that they took this 3-week treatment, with no additional toxicity and had such outstanding results. Kersten's right, he has no need to defend the data anymore. It's out there as top line and there's more coming as soon as the NLM publishes the complete data on clinical trials.gov momentarily.
You can bet that Mr Kirsten has a major PR just waiting for when that data is published. Question is, where are you going to be?
North Shore Research profile picture
@BioSlammer Incorrect.

Im not short nor am I looking for cheaper shares.

This stinker is headed to $2 shortly and I wont touch

Why no pre-BLA meeting after 13 months. Most companies have a pre-BLA meeting within 4 months after data release. Here is just one example of a company being transparent:



You do seem angry

North Shore Research profile picture
@BioSlammer Hows that Hernia!

You seem angry

Another Mountain's Rock Investing profile picture
People still talking about this one? Give up imo!
North Shore Research profile picture
The last time the words "pre-BLA" were mentioned by CVM was on the 7/7/21 PR:

“We are now preparing to meet with the FDA for a pre-Biologics License Application (BLA) meeting and seek and file for FDA approval."

Since that date, there has been NO MENTION of the "pre-BLA" meeting! None. Scrubbed from subsequent PRs and SEC filings like the 10Q and 10K.

What is Geert hiding?

He did say he "hopes" to have a pre-BLA meeting by 12/31/22 on the Reddit chat. Hopes!

What is Geert hiding?

Most companies have their pre-BLA meeting within 6 months. Its going on 13 months for CVM!
@North Shore Research The same comment from you, cut and pasted everywhere. We get it, you’re short. There will be a pre-BLA, and subsequent steps leading to and including approval. The data and readinesses for manufacturability are the ultimate determinants here, not your personal declaration of a “normal” timeline, nor your interpretation what has been said or not said by the company.
North Shore Research profile picture
@jcalene Im not short nor do I have any position (stock or options)

Just providing unbiased info

You seem angry

Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About CVM

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CVM

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.